Noreen McGurrin Griffin

Advanced Immunomodulating Multi-receptor System (“AIMS “). The AIMS platform is developing noroxymorphone and proenkephalin analogs as a new class of immunomodulating drugs. Our platform is designed to be a fundamentally new treatment approach in the infectious disease and autoimmune market that are designed to overcome key issues associated with current therapies, including serious adverse events ("SAE") drug resistance, short duration of response, negative impact on the human microbiome,